An Evaluation of the Effectiveness of Dual Focus Soft Contact Lenses in Slowing Mypoia Progression

This study is ongoing, but not recruiting participants.
Visioncare Research Ltd.
Information provided by (Responsible Party):
Coopervision, Inc. Identifier:
First received: November 14, 2012
Last updated: January 20, 2016
Last verified: January 2016
The purpose of this study is to determine whether a new type of soft contact lens with a unique optical design (dual focus) is effective at slowing the progression of myopia (near-sightedness) in children.

Condition Intervention Phase
Device: Dual Focus Soft Contact Lens
Device: Single Vision Soft Contact Lens
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Multicentre Dispensing Clinical Evaluation of MiSight® Lenses

Resource links provided by NLM:

Further study details as provided by Coopervision, Inc.:

Primary Outcome Measures:
  • Change in refractive error relative to baseline [ Time Frame: yearly for 3 years ] [ Designated as safety issue: No ]
  • Change in axial length relative to baseline [ Time Frame: yearly for 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Incidence of adverse events [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 300
Study Start Date: November 2012
Estimated Study Completion Date: May 2019
Estimated Primary Completion Date: May 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Dual Focus Soft Contact Lens
Dual Focus Soft Contact Lens
Device: Dual Focus Soft Contact Lens
Placebo Comparator: Single Vision Soft Contact Lens
Single Vision Soft Contact Lens
Device: Single Vision Soft Contact Lens


Ages Eligible for Study:   8 Years to 12 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Be between 8 and 12 years of age inclusive.
  • Best-corrected visual acuity by manifest refraction of +0.10 logMAR.
  • Spherical Equivalent Refractive Error between -0.75 and -4.00 D inclusive astigmatism: < -0.75 D anisometropia: < 1.00 D
  • Possess wearable and visually functional eyeglasses.
  • Agree to wear the assigned contact lenses for a minimum of 10 hours per day, - at least 6 days per week, for the duration of the 3 year study.

Exclusion Criteria:

  • Subject has previously or currently wears contact lenses or rigid gas permeable contact lenses, including orthokeratology lenses.
  • Subject is currently or within 30 days prior to this study has been an active participant in another clinical study.
  • Current or prior use of bifocals, progressive addition lenses, atropine, pirenzepine or ANY other myopia control treatment.
  • Regular use of ocular medications (prescription or over-the-counter), artificial tears, or wetting agents.
  • Current use of systemic medications which may significantly affect contact lens wear, tear film production, pupil size, accommodation or refractive state.
  • A known allergy to fluorescein, benoxinate, proparacaine or tropicamide.
  • Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction.
  • Any ocular, systemic or neuro-developmental conditions that could influence refractive development.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01729208

Canada, Ontario
University of Waterloo School of Optometry
Waterloo, Ontario, Canada, N2L 3G1
University of Minho Clinical & Experiment Optometry Research Lab
Braga, Portugal, 4710-057
National University of Singapore Faculty of Medicine
Singapore, Singapore, 117597
United Kingdom
Aston University Ophthalmic Research Group
Birmingham, United Kingdom, B4 7ET
Sponsors and Collaborators
Coopervision, Inc.
Visioncare Research Ltd.
  More Information

Responsible Party: Coopervision, Inc. Identifier: NCT01729208     History of Changes
Other Study ID Numbers: CVI08008 
Study First Received: November 14, 2012
Last Updated: January 20, 2016
Health Authority: United Kingdom: Research Ethics Committee

Keywords provided by Coopervision, Inc.:
myopia progression
myopia control processed this record on May 26, 2016